Sale Alert!

Check out our latest deals! NEOPARŪ

  Home > Pet Direct > Pet Prescription Drugs > Pet RX H-L > Pet RX (L) >

Loxicom Injection
Loxicom Injection
Loxicom Injection

Rx Required  / Vet Prescription Form will be needed to send this item.
At Check Out, Please choose your method of submission for your Prescription Product.
Click here for prescription form.
Loxicom (5 mg/mL meloxicam) Injection, by Norbrook, is an FDA-approved injectable non-steroidal anti-inflammatory (NSAID) medication for use in dogs and cats. Controls post-operative pain/inflammation in cats associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery, and pain/inflammation associated with OA in dogs for up to 24 hours.

Item# Item Name Our Price Qty Add
567-046678 Loxicom Injection 10ml
567-046679 Loxicom Injection 20ml
Check the items you wish to purchase, then click

Each ml contains:

Meloxicam 5 mg/ml
Ethanol, anhydrous 150mg/ml


Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery.

Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Dosage & Administration

Single administration of 0.2mg Meloxicam/kg bodyweight (i.e. 0.4ml/10kg).

Musculo-skeletal disorders: Single subcutaneous injection.

Loxicom 1.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg Meloxicam/kg bodyweight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours):
Single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Single administration of 0.3mg Meloxicam/kg bodyweight (i.e. 0.06ml/kg).

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: Single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Particular care should be taken with regard to the accuracy of dosing.

Avoid introduction of contamination during use.

Contraindictions, Warnings etc

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2kg.

Typical adverse reactions of non-steroidal anti-inflammatory drugs NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and
should be treated symptomatically.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia.

If adverse effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Do not use an oral follow-up therapy containing meloxicam or other NSAIDs in cats, as no safe dosage for repeated oral administration has been established.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. In the case of overdose symptomatic treatment should be initiated.

Operator warnings: Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

Pharmaceutical Precautions

This veterinary medicinal product does not require any special storage conditions.

Shelf-life after first opening the container 28 days.

Do not use after the expiry date stated on the carton and the bottle.

Dispose of any unused product and empty container in accordance with guidance from your local waste regulation authority.

Further Information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, antiexudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase 2 (COX 2) to a greater extent than cyclooxygenase 1 (COX 1).

Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73?g/ml in dogs and 1.1 ?g/ml in cats were reached approximately 2.5 hours and 1.5 hours postadministration, respectively.

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. More than 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats. In dogs, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative
and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Meloxicam is eliminated with a half-life of 24 hours in dogs and 15 hours in cats. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

Share your knowledge of this product with other customers... Be the first to write a review

Browse for more products in the same category as this item:

Pet Direct > Pet Prescription Drugs > Pet RX H-L > Pet RX (L)
Breeder Direct > Prescriptions / RX > Prescriptions H - L > Prescriptions (L)

Social Tab
Are you a fan of A to Z Vet Supply?
Hide Bar

Read our latest blog post...